% | $
Quotes you view appear here for quick access.

công ty Questcor Pharmaceuticals Message Board

  • holidayinnandout holidayinnandout Jan 27, 2013 8:11 PM Flag

    MF Conclusion Was 5 Recommend Buy Or OutPerform And 4 Say Hold

    Good news
    QCOR..beating market expectations for revenue and earnings in each quarter for two years,
    great product, good management,
    pays a tidy dividend ($.80 per share and yielding over 3%),
    strong fundamentals going forward, exceeding expectations,
    sales of $865 million including $424 million in the previous year,
    substantial cash flows from its operations,
    aggressive marketing, increased scope of treatment coverage,
    could be acquired by big pharma from previous MF article,
    QCOR purchased BioVectra (the major supplier for Achtar) for $50 million cash to firm up its supply side and to prevent competition for Achtar from entering the market.
    Negative news
    Aetna still covers Achtar on a case by case basis (info from Aetna and QCOR) even though they claimed there would be limited coverage....Every couple of weeks a research group would print the Aetna story as if it was new news.
    The U.S. agency investigating promotional practices for marketing is a Philadelphia District Attorney somewhere in Philadelphia, recent news about anything.....
    Cerium Pharmaceuticals is a garage connected to a house in (Maryland??)...Someone claimed that they sought orphan drug status for a synthetic form of Achtar....QCOR should have orphan drug protection until at least 2017.
    Trading at a substantial discount due to negative news but is an extremely attractive investment
    with significant upside potential
    Was a $50 stock in 2012 before negative news started around August-September, 2012

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
93.600.00(0.00%)Aug 14 4:00 PMEDT